Fortis Healthcare Ltd NSE  /  BSE

Healthcare, Mid Cap

20 Jan 2020 | 04:15 PM

1.50 (1.06%)

Independent Research


We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts positive since 02-Aug-2019

    Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 02-Aug-2019 at a price of 117.95.

  • Valuation Rating

    Moderately undervalued

    Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.

  • MT Tech Trend

    Trend negative since 10-May-2019

    The forty day Medium Term Technical Trend is negative since 10-May-2019. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is 126.979.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -1.970.

Risk parameters

  • Risk Zone


    The stock has been on the moderate-sensitivity level since 02-Aug-2019.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 202%.

  • Beta

    48 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 48%.

  • Correlation

    0.33 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.14.57 The medium term value at risk is estimated at 14.57 or 0.12010%

    The value at risk is estimated at 14.57. The risk is therefore 0.12010%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    55.94 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    23.24 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    2.41 High discount to expected growth due to base effect

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).

  • Dividend Yield

    0% No dividend

    The company is not paying a dividend.

  • Global Evaluation


    The stock is classified in the neutral zone since 02-Aug-2019.